In March 2013, Fagron entered into a partnership with NAFA Medical in Saudi Arabia for the purpose of introducing Fagron’s products and concepts onto the Saudi market. Saudi Arabia is investing heavily in developing its pharmaceutical infrastructure in order to facilitate the increasing demand for enhanced tailor-made compounded products. The strong growth of private medical care as well as population growth in the Kingdom are major contributory factors in this regard. The partnership with NAFA Medical reinforces Fagron’s position as global market leader in pharmaceutical compounding and constitutes an important step for the further roll-out of Fagron’s product range in the Middle East.
At present, Fagron is active in 30 countries on five continents. In 2013, Fagron will further strengthen its position as global market leader through an active buy-and-build strategy, starting up greenfields and robust organic growth.